Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
Clinical and Molecular Hepatology
;
: 49-59, 2015.
Article
in English
| WPRIM
| ID: wpr-64643
ABSTRACT
BACKGROUND/AIMS:
Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells.METHODS:
Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis.RESULTS:
Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin.CONCLUSIONS:
Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenylurea Compounds
/
Quinazolines
/
Silymarin
/
Drug Screening Assays, Antitumor
/
Signal Transduction
/
Down-Regulation
/
Cell Survival
/
Niacinamide
/
Carcinoma, Hepatocellular
/
Cell Line, Tumor
Limits:
Humans
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS